Drug Testing Industry And Pharmaceutical Company Ask Court To Pause Trump’s Marijuana Rescheduling Move

An industry association that represents drug testing companies and a cannabis-focused biopharmaceutical corporation are asking a federal appeals court to block the Trump administration from moving forward with federal marijuana rescheduling while ongoing litigation challenging the reform is considered—claiming that cannabis is a “dangerous drug that destroys lives.”

The National Drug and Alcohol Screening Association (NDASA), along with MMJ International Holdings and its subsidiaries, argue in the new filing on Tuesday that the cannabis rescheduling move is “a brazen agency overreach in which the Acting Attorney General ignored restrictions on his authority set by Congress—and a binding decision of this Court—to carry out one of the most sweeping reductions in restrictions on a dangerous narcotic in the history of the Controlled Substances Act (CSA).”

“Nearly fifty years ago, this Court held that the Attorney General lacks authority to unilaterally decide how marijuana ought to be restricted—that is, which Schedule it should be placed under—pursuant to the CSA. The Court explained that Congress constrained the Attorney General’s authority by requiring him both to secure recommendations from the Secretary of Health and Human Services (HHS) and to make detailed findings through a formal rulemaking on the record. While the CSA contains a limited bypass of those procedures to allow the Attorney General to ensure that the U.S. complies with certain treaties…this Court made clear that the bypass cannot be invoked when the Attorney General is simply deciding to move a drug between two Schedules under the CSA, either of which would comply with treaty obligations.”

“The Department of Justice complied with this Court’s construction of the CSA for over four decades—until now,” the joint motion for a stay pending review that was filed before the U.S. Court of Appeals for the District of Columbia Circuit argues.

While HHS had issued a recommendation to reschedule marijuana during the Biden administration, the recent move by the Trump Department of Justice canceled ongoing proceedings related to that proposal and issued a new final rule.

Keep reading

Exposing The Great Acid Reflux Scam

•Many commonly prescribed medications are given to patients despite the risks often outweighing the benefits.

•Acid-suppressing drugs are among the worst offenders, with their overuse fueled by a lack of understanding about the crucial role of stomach acid throughout the body or that acid reflux is due to too little stomach acid (as the stomach acid of digestion gives the stomach’s opening a signal to seal and not let any more food in).

•Deficient stomach acid causes many chronic health problems (e.g., macular degeneration, a myriad of autoimmune disorders such as asthma, and less overt forms of reflux that cause many common diseases of the ears, nose, and throat such as allergies, coughs, and sinusitis).

•Acid blocking medications cause a variety of severe side effects, including a 19% increased risk of death and a comparable increase in cardiac events, kidney or liver disease, numerous infections, and bone damage.

•Thankfully, many safe natural treatments can effectively address acid reflux and many of the complications of a chronic stomach acid deficiency.

In the U.S., 66% of adults are estimated to have at least one prescription, and the average person has nine filled annually. As an awake physician, one of the most depressing aspects of my work is seeing patients, especially the elderly, weighed down by numerous prescriptions that frequently do more harm than good.

For example, as I showed here, statins provide a negligible benefit (e.g., at best, taking them for five years extends one’s lifespan by 3-4 days) but create significant side effects such as severe muscle pain and cognitive impairment for 20% of users.

This tragic situation is best demonstrated by a 2007 study which showed that simply discontinuing the least necessary prescriptions resulted in a 23% reduction in the death rate and an 18.2% decrease in hospital referrals. Sadly, since the trend in medicine is always to have people on more drugs, data like this has had no effect on the practice of the overprescription of medications.

Keep reading

The Crisis Creators – Why Behavioral Health Makes Everything Worse

If anyone hasn’t figured out yet where too much of America’s health problems begin, look no further than the behavioral health industry. It’s time to take a serious look.

While the federal government is in an all-out offensive to uncover fraud in State Medicaid programs, the real fraud lies in the psychiatric diagnosing that has gone unchecked for a hundred years and brought the nation to a mental health crisis.

Just this month alone, the Health and Human Services Secretary, Robert F. Kennedy, Jr., has begun a national campaign to reduce the use of psychiatric drugs by publishing “deprescribing” guidance and training for doctors for any number of the tens of millions of Americans who are taking Selective Serotonin Reuptake Inhibitors (SSRIs) commonly referred to as antidepressants.

Here’s the truth. The modern mental health model of diagnosis and drug treatment is an enormous failure. People have been harmed for years using antidepressants, and go figure, the medical community admits it’s hard to get off prescription mind-altering drugs. The goal of the HHS Secretary is to finally make drugs one of many options for “treatment” of mental illnesses. But is that enough? Is that really the answer to over-prescribing?

It’s a fact. Americans can’t get the drugs without a mental disorder diagnosis, and the diagnoses are not based on science. In other words, there isn’t anything broken in anyone’s brain that can be medically measured…no X-ray, CAT Scan, blood or urine test can identify any of the alleged mental disorders. And, the fact is, if an abnormality was discovered in the brain, most likely a neurologist would be utilized…not a psychiatrist. Neurologists study brain disease, and psychiatrists study behavior. A very big difference that has been ignored in the modern mental health model.

Keep reading

FDA Ousts Another Top Official: Who’s Behind the Shakeup — and Why?

Tracy Beth Høeg, M.D., Ph.D., an epidemiologist and sports physician who supported studying — and reducing — the recommended childhood vaccination schedule, was fired by the U.S. Food and Drug Administration (FDA). Høeg was acting director of the FDA’s Center for Drug Evaluation and Research (CDER).

In a post on X last Friday, Høeg wrote that she “learned so much” and is leaving the FDA “with no regrets.”

And in an interview with MD Reports published shortly after her firing, Høeg said she first learned about the agency’s plans to fire her earlier in the week, through media reports.

On May 15, two unnamed FDA officials offered her the choice to resign or be fired. When she refused to resign, she was fired on the spot.

“I said I didn’t want to resign,” Høeg told MD Reports. “I said I’m not signing a letter of resignation if it’s not my choice.”

During her time at the FDA, Høeg was involved in several research initiatives broadly tied to the Make America Healthy Again (MAHA) agenda. According to The New York Times, this included work on an “intense investigation” last year that linked the COVID-19 vaccines to “at least” 10 child deaths.

Høeg also authored a report recommending that the number of diseases covered by the recommended childhood vaccination schedule be reduced from 17 to 11.

In January, U.S. Health Secretary Robert F. Kennedy Jr. implemented these recommendations. However, in March, a federal court issued a stay pausing adoption of the new schedule.

According to The Associated Press, Høeg was most recently involved in the FDA’s review of a petition to add new warnings to antidepressants about risks to pregnant women, “including fetal abnormalities that could lead to autism and other disorders.”

Keep reading

Trump Praises Liberal Billionaire Mark Cuban at White House TrumpRX Event, Says Kamala Harris Endorsement Was “a Big Mistake”

Mark Cuban, the liberal former Dallas Mavericks owner and Shark Tank co-host, made an appearance alongside President Trump at the White House on Monday to announce an expansion of the President’s TrumpRX website. 

Cuban’s online pharmacy, Cost Plus Drugs, along with Amazon Pharmacy and GoodRx, are set to list over 600 generic drugs on TrumpRX at lower costs for consumers. Cuban said 559 of the drugs come from his company.

“I’ve been the biggest proponent of TrumpRX.com,” Cuban said in brief remarks at the event. “Republicans want cheaper drugs. Independents want cheaper drugs. Democrats want cheaper drugs. And together, I think we’re going to do something special.”

However, Cuban has never supported Trump, frequently attacking him and supporting Kamala Harris in 2024.

One America News Network’s Daniel Baldwin asked the President about Cuban’s history as a Never Trumper, and Trump squashed the beef.

“he’s got a good company, and he’s going to do a lot of business with this,” Trump said, describing Cuban as “very gracious.” He continued, “I think I have a lot of respect for Mark, frankly, and I always have.”

Keep reading

Ozempic Face? Try Ozempic Pancreatitis: Inside the GLP-1 Profit Model

If you thought “Ozempic face” was bad, wait till you hear what it’s doing inside the body.

A massive study involving 16 million people found GLP-1 users had a 9.09 times greater risk of pancreatitis, 4.22 times greater risk of bowel obstruction, and a 3.67 times greater risk of stomach paralysis.

And if you’ve ever had pancreatitis, it is “quite a painful experience.”

What you’re hearing on the news about Ozempic is still too little, too late.

Here’s the story you’re not getting about Ozempic, the business model behind it, and why a growing number of researchers believe another pharmaceutical disaster is already unfolding in real time.

In early 2023, JP Morgan hosted its annual healthcare conference—a private, invitation-only event it describes as “the industry’s biggest gathering.”

The keynote speakers included the chairman of JPMorgan Chase, the CEO of Eli Lilly, and several managing directors of major healthcare venture capital firms.

The fourth keynote was Dr. Robert Califf.

His day job at the time: Commissioner of Food and Drugs for the United States Food and Drug Administration.

Hmm…

This wasn’t a public health symposium. It wasn’t an academic conference.

It was specifically designed for large investors, and its explicit purpose was to set the pharmaceutical industry’s financial priorities for the year ahead.

A pharmaceutical safety advocate named Kim Witczak obtained what she could from the conference’s public-facing website.

But what was being said behind closed doors?

Keep reading

How a Scientific Cartel Protects Fraudsters and Rakes in Billions of Taxpayer Dollars

I was 22 when my grandmother forgot me.

It took her 12 years to die from Alzheimer’s. It started with little things, like where her glasses were or what day it was. Soon she didn’t know who I was. For a while, she addressed me as her son, but then, as the disease ate away more of her mind, she forgot him too. Then I was the young, handsome version of her husband, until he too faded away. After a while, I was just a nice young man who came to visit her.

The rest of the time, she was afraid: waking up in an unfamiliar world, surrounded by people she’d never met, confused that she wasn’t back home in Minnesota, where she’d grown up. It hit my mom the hardest. She did everything she could to take care of her own mother, watching the brilliant, kind woman she knew rot into a husk of her former self.

My grandmother died on Christmas Eve. As sad as it was, it was a blessing for my mom, who was finally freed from her duty of watching the woman she loved the most waste away.

The Alzheimer’s Researcher Who Became a Poster Child for Academic Fraud

Sylvain Lesné, a neuroscientist at the University of Minnesota, published a paper in Nature in 2006 claiming to identify a specific amyloid beta protein assembly as the direct cause of memory impairment in Alzheimer’s. This reinvigorated the amyloid hypothesis at a moment when skepticism about it was ramping up. The National Institutes of Health (NIH) devoted $1.6 billion to projects that mention amyloids in 2022 alone, nearly half of all federal Alzheimer’s funding that year. Lesné was a star.

But there were rumblings. Numerous amyloid drugs made it to trials with billions invested by pharmaceutical companies. They failed repeatedly. A question arose in the pharmaceutical community: How can this be right? How can the trials keep failing if the underlying research is correct? 

In 2022, the Vanderbilt neuroscientist Matthew Schrag uncovered evidence that images in Lesné’s paper had been manipulated. Science magazine found more than 20 suspect papers by Lesné, with over 70 instances of possible image tampering. Nature retracted the paper in June 2024. Every author except Lesné signed the retraction. Lesné himself resigned from his tenured position at the University of Minnesota on March 1, 2025, three years after his fraud was exposed.

More news and details trickled out over time. Charles Piller’s 2025 book Doctored talks about the Amyloid Mafia, a nickname for a network that had prioritized novelty over replication and marginalized dissenters for decades. Anyone questioning the amyloid gospel was pushed out and watched their funding vanish.

When I first picked up that Science article, I hadn’t considered academic fraud as something that was real and widespread. As I thought about it more, I was filled with a deep, bitter hatred. For his own pride, greed, and acclaim, this man had doomed millions of people like my grandmother to slow, horrible deaths and millions more like my mom to agonizing years as caregivers.

Lesné resigned, but was still rich. None of his grant money was clawed back. The system that was supposed to catch this—peer review, university compliance, journal editorial boards—failed repeatedly for years.

Keep reading

Harvard-Trained MD Says ‘Coercive’ Vaccine Push Shattered Trust and Has Harris Voters Questioning the Experts

During an exclusive interview with The Western Journal this week, Dr. Monique Yohanan said Americans have a right to question the country’s vaccine schedule and must learn to advocate for themselves in medical settings.

Yohanan, who is director of the Center for Better Health at Independent Women, has an impeccable academic resume.

She received her medical degree from the Dartmouth/Brown Program and a Master of Public Health from Johns Hopkins. She did her residency in internal medicine at Harvard and a fellowship in geriatrics at Stanford.

In addition, Yohanan has held faculty appointments while maintaining active licensure and board certification in internal medicine.

Her CV, however, clashes with mainstream media narratives regarding vaccine skepticism. Those who pose questions about vaccinations are typically tagged as uneducated, misinformed, and are told to “trust the science.”

So why would someone with over 20 years of experience in clinical medicine, technology, and health policy speak out like this? Because she believes vaccination has become so politicized and deified that it’s harming patients.

“I feel like there’s a lot of dismissal of MAHA [Make America Healthy Again],” she said. “There’s a lot of dismissal of people who have questions about vaccines. There are people, historically, who framed the vaccine schedule as ‘You’re pro vaccine if you agree to every single vaccine, and that’s that.’ If you get all 27 shots and you shut your mouth and don’t say a word, then you’re a good person.’”

“And God forbid, you might say, ‘Well, I’m OK with my kid getting the shot for measles or for whooping cough, but do I really need the shot for hepatitis B?’”

Yohanan said that in California, “if you don’t get the shot for hepatitis B, your kid can’t go to public school.” And she’s correct. The state doesn’t even allow for religious or personal belief exemptions.

“That’s not a public health policy. To me, that is very coercive,” she added. “With COVID, what we had is so much, to me, of an overstatement of confidence that people started questioning everything, and so that’s where I come from, is that people are willing to have a more nuanced discussion.”

Yohanan also highlighted how California doctors are financially incentivized by Medicaid to get as many people vaccinated as possible.

Keep reading

‘You’ve Got to be Freaking Kidding Me’: U.S. Military Spends Over $700 Million for Ozempic and Other GLP-1 Weight Loss Meds

Military personnel criticize the hundreds of millions spent on weight loss medications as a misguided approach to addressing the obesity crisis in the U.S. Armed Forces.

A report from the American Security Project in 2025 revealed that approximately 68 percent—two out of three—of the military’s Reserve and National Guard forces are classified as overweight.

Subsequent to this report, Secretary of War Pete Hegseth expressed his concern on X, stating, “Completely unacceptable. This is what happens when standards are IGNORED – and this is what we are changing. REAL fitness & weight standards are here. We will be FIT, not FAT.”

Was the solution found in raising the bar for “REAL fitness & weight standards?” Perhaps they were. However, some startling revelations concerning weight loss have emerged, with RealClearInvestigations dubbing this disclosure the “Waste of the Day.”

Since 2021, the military has allocated nearly $726 million for Ozempic and other GLP-1 weight loss medications, with $274.6 million spent in fiscal year 2025, as revealed by spending records acquired by Open the Books.

This expenditure encompasses 102,597 individual purchases, all made through the Defense Logistics Agency for “troop support.” The majority of the funds were directed to the wholesale pharmaceutical company Cencora. Over a dozen varieties of GLP-1 medications were acquired, including Wegovy, Mounjaro, and Trulicity.

Many individuals—and taxpayers alike—who have served in the military are infuriated.

Lt. Ted Macie, a retired Navy Medical Service Corps officer, was appalled. He informed The Gateway Pundit that data obtained from the Defense Medical Epidemiology Database (DMED) indicate that obesity rates have surged in the military over the last decade.

From 2016 to 2019, an average of 13,863 cases of overweight and obesity were documented across all branches of service. This average rose to 21,969 between 2020 and 2023. Remarkably, there was a 190 percent increase during this period, with cases soaring from 12,249 to 35,531.

Keep reading

Psychiatry Won’t Pull Paper on Misleading Safety of PAXIL, Despite Massive Drug Settlement, Consumers Get “Expression of Concern”

A D.C. judge just sided with a long‑discredited Paxil study instead of the kids it was used to sell drugs to. GlaxoSmithKline has already paid $3 billion for fraud that included how it pushed Paxil for children and supported this very study, yet the article still stands in the medical record.  Those who rush to always defend psychiatry as “experts” of the human condition should really look at the bigger picture.

According to the lawsuit, that study falsely claimed Paxil was safe and effective for depressed teens, even though the company’s own trial data did not show real benefit and did show serious safety concerns, including suicidal thoughts and behavior. The case explains why lawyer George Murgatroyd went after the journal and its publisher for continuing to publish and sell the article, how the court’s ruling let psychiatry’s publishing system avoid full accountability once again, and how consumers were left with only a small warning label on the paper instead of the clear retraction many believe is needed.

At the center of this case is attorney George W. Murgatroyd III, a product‑liability lawyer who has represented families whose children died by suicide after taking Paxil. Murgatroyd sued the American Academy of Child and Adolescent Psychiatry and the publisher Elsevier, arguing they were still “publishing, distributing, and selling a fraudulent scientific article” that misleads the public and endangers adolescent mental health, while charging readers to access it. He asked the D.C. Superior Court to treat that article as a deceptive practice under the District’s consumer‑protection law and to order a full retraction.

In March 2026, Judge Robert Okun dismissed his case. The judge did not say Study 329 was honest or reliable. Instead, he ruled that Murgatroyd lacked legal standing and that a journal article is not a “consumer good or service” under that particular law, so the court could not use that statute to force a retraction. In practical terms, the decision shields the journal and publisher: they keep the article online, charging for access, under the protection of free‑speech arguments rather than being treated like sellers of a defective product. For an industry already tied to a historic fraud settlement over this very drug and trial, it is another escape.

Murgatroyd’s work still produced one real gain for the public. After he filed his complaint, JAACAP finally attached an “expression of concern” to Study 329 in 2025, warning readers that serious issues have been raised about the article and that further review is underway. That warning label stays with the paper and marks it as disputed rather than trustworthy, a change that likely would not have happened without Murgatroyd pushing. In a landscape where a flawed study helped justify giving a risky drug to teens, naming him and his effort matters: he forced at least a small, visible sign of truth into the official record, even as the larger fight for justice and a full retraction continues.

Keep reading